EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways

Daniela Lucente, Stefania Bellino iD, Anna La Salvia iD

Genes · 10.11.2025 · 16 (11) · 1352

DOI: 10.3390/genes16111352 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 10.11.2025. Verfasst von Daniela Lucente und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed to treat type 2 diabetes mellitus, are now being investigated as agents in oncology. Recent preclinical studies have demonstrated their antitumor activity in several solid malignancies, including pancreatic, colorectal, breast, and prostate. Importantly, GLP-1 RAs modulate key signalling pathways such as PI3K/Akt, PKA, and AMPK, and exert anti-inflammatory effects by reducing cytokine production and macrophage infiltration. Preclinical data support their antineoplastic activity in vitro and in vivo, particularly by inhibiting tumour growth and metastasis. Nevertheless, there are ongoing concerns about tumorigenic effects in certain cancer types. This review critically examines the molecular mechanisms by which GLP-1 RAs influence cancer cell proliferation, apoptosis, angiogenesis, and inflammation, and emphasizes the need for further clinical studies to determine their therapeutic relevance. It also proposes assessing GLP-1 RAs as adjuncts in the management of solid tumours.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsNeoplasmsAntineoplastic AgentsHumansSignal TransductionAnimalsGlucagon-Like Peptide-1 ReceptorApoptosisCell Proliferation

Stichwörter der Autor:innen

GLP-1 receptor agonistsantitumor activityinflammation and cancermolecular mechanismssolid tumours

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsAntineoplastic AgentsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy.

ORCID-Profile: Stefania Bellino, Anna La Salvia

Zitieren

APA

Lucente, D., Bellino, S., & La Salvia, A. (2025). GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways. Genes, 16(11), 1352. https://doi.org/10.3390/genes16111352

Vancouver

Lucente D, Bellino S, La Salvia A. GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways. Genes. 2025;16(11):1352. doi:10.3390/genes16111352

BibTeX
@article{Lucente2025,
  author = {Lucente, Daniela and Bellino, Stefania and La Salvia, Anna},
  title = {GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways},
  journal = {Genes},
  year = {2025},
  volume = {16},
  number = {11},
  pages = {1352},
  doi = {10.3390/genes16111352}
}
Kostenlos starten →